Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)

• Egile Nagusiak: Julia-Tatjana Maul (Egilea), Melike Ak (Egilea), Sara E. Cerminara (Egilea), Simona Steinmann (Egilea), Elisabeth V. Goessinger (Egilea), Anna Darzina (Egilea), Iker Oyanguren Monferrer (Egilea), Raphael Micheroli (Egilea), Georgios Kokolakis (Egilea), Elisabeth Roider (Egilea), Felix Oestereich (Egilea), Eva Mateu (Egilea), Martina Burlando (Egilea), Alexander A. Navarini (Egilea), Thomas Kündig (Egilea), Lara Valeska Maul (Egilea)
• Formatua: Liburua
• Argitaratua: Medical Journals Sweden, 2024-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight...